The Prevention of Thromboembolic Complications Associated With Coil Embolization

Coil Embolization and Thromboembolic Complications in Patients With Ruptured Aneurysms

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05512546

Enrollment

200

Registered

2022-08-23

Start date

2017-02-10

Completion date

2020-12-10

Last updated

2022-08-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aspirin, Clopidogrel, Coil Embolization, Prevention, Thromboembolic Stroke

Brief summary

Clopidogrel has been to be reported to be superior to aspirin for the prevention of thromboembolic complications associated with coil embolization in patients with ruptured aneurysms.

Interventions

DRUGAspir-Low Pill

patients were prescribed 75 mg/day of either aspirin

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

45 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

* All the patients enrolled in the study underwent MRI and Angiography. * Participants included in the study were confirmed on assessment, and verified for ruptured aneurysm by imaging using either computed tomography (CT) or MRI.

Exclusion criteria

* Patients with any history of sensitivity or reaction to aspirin, or any contraindication for MRI, were excluded from the study.

Design outcomes

Primary

Measure	Time frame	Description
High Intensity Areas	at 24 hours	post procedural

Secondary

Measure	Time frame	Description
High Intensity Areas	at 6 months	Post procedural

Countries

Pakistan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026